

## Legislation Details (With Text)

Agondo Itom				
Agenda Item		Status:	Passed	
		In control:	BOARD OF SUPERVISO	DRS
6/5/2018		Final action:	6/5/2018	
Consider reco the purchase	ommendations re of pharmaceutic	egarding Waivers als for the 340B (	of Competition under Count Contract Pharmacy Network	ty Code Section 2-39 for Program, as follows:
Network Prog competitive bi exclusivity ag exceed \$3,10	ram from Ameris idding since Con reements, and to 0,000.00 per yea	sourceBergen Dru atract Pharmacies o ensure 340B Pro ar and an aggrega	ig Company (not a local ver and Amerisource Bergen D ogram compliance for an an	ndor) without requiring Drug Company maintain nount up to but not to
Network Prog Contract Pha Program com	ram from Cardin rmacies and Car pliance for an ar	al Health (not a lo dinal Health main nount up to but no	ocal vendor) without requirin tain exclusivity agreements of to exceed \$2,500,000.00	ng competitive bidding since , and to ensure 340B per year and aggregate
c) Authorize the Purchasing Manager to procure pharmaceuticals for the 340B Contract Pharmacy Network Program from McKesson (not a local vendor) without requiring competitive bidding since Contract Pharmacies and McKesson maintain exclusivity agreements, and to ensure 340B Program compliance for an amount up to but not to exceed \$200,000.00 per year and aggregate costs not to exceed \$600,000.00 for the period July 1, 2018 through June 30, 2021;				
d) Authorize the Purchasing Manager to amend purchasing contract BL14003 with McKesson to increase the amount from \$150,000.00 to \$180,000.00 for Fiscal Year 2017-2018 for the 340B Contract Pharmacy Network Program;				
e) Approve and authorize the Director of the Public Health Department to execute or terminate Agreements with local 340B Contract Pharmacies to ensure sustainability of the program and access for patients throughout Santa Barbara County, without returning to the Board with a separate amendment, provided that any such revisions are within the scope of approved Purchasing authorizations, including applicable waivers of competition; and				
f) Determine that these activities are exempt from California Environmental Quality Act (CEQA) review per CEQA Guideline Section 15378(b)(4), since the recommended actions are government fiscal activities which do not involve commitment to any specific project which may result in a potentially significant physical impact on the environment.				
PUBLIC HEA	LTH DEPARTMI	ENT		
1. Board Lette	ər			
Ver. Action B	у	Ac	ion	Result
	Consider reco the purchase a) Authorize t Network Prog competitive bi exclusivity ag exceed \$3,10 July 1, 2018 t b) Authorize t Network Prog Contract Phan Costs not to e c) Authorize t Network Prog Contract Phan costs not to e c) Authorize t Network Prog Contract Phan compliance for exceed \$600, d) Authorize t increase the a Contract Phan contract Phan compliance for exceed \$600, d) Authorize t increase the a Contract Phan contract Phan compliance for exceed \$600, d) Authorize t increase the a Contract Phan for patients th amendment, p authorizations f) Determine t per CEQA Gu activities which significant phy PUBLIC HEA	Consider recommendations re the purchase of pharmaceutic a) Authorize the Purchasing M Network Program from Ameria competitive bidding since Cor exclusivity agreements, and to exceed \$3,100,000.00 per yea July 1, 2018 through June 30, b) Authorize the Purchasing M Network Program from Cardin Contract Pharmacies and Car Program compliance for an ar costs not to exceed \$7,500,00 c) Authorize the Purchasing M Network Program from McKes Contract Pharmacies and McF compliance for an amount up exceed \$600,000.00 for the per d) Authorize the Purchasing M increase the amount from \$15 Contract Pharmacy Network F e) Approve and authorize the Agreements with local 340B C for patients throughout Santa amendment, provided that any authorizations, including appli f) Determine that these activiti per CEQA Guideline Section activities which do not involve significant physical impact on PUBLIC HEALTH DEPARTMI	<ul> <li>6/5/2018 Final action:</li> <li>Consider recommendations regarding Waivers the purchase of pharmaceuticals for the 340B C</li> <li>a) Authorize the Purchasing Manager to procurr Network Program from AmerisourceBergen Drocompetitive bidding since Contract Pharmacies exclusivity agreements, and to ensure 340B Preseced \$3,100,000.00 per year and an aggregative 1, 2018 through June 30, 2021;</li> <li>b) Authorize the Purchasing Manager to procurr Network Program from Cardinal Health (not a locontract Pharmacies and Cardinal Health (not a locontract Pharmacies and Cardinal Health main Program compliance for an amount up to but not costs not to exceed \$7,500,000.00 for the period</li> <li>c) Authorize the Purchasing Manager to procurr Network Program from McKesson (not a local v Contract Pharmacies and McKesson maintain exceed \$600,000.00 for the period July 1, 2018</li> <li>d) Authorize the Purchasing Manager to amend compliance for an amount up to but not to exceed \$600,000.00 for the period July 1, 2018</li> <li>d) Authorize the Purchasing Manager to amend compliance for an amount up to but not to excee exceed \$600,000.00 for the period July 1, 2018</li> <li>d) Authorize the Purchasing Manager to amend and increase the amount from \$150,000.00 to \$180 Contract Pharmacy Network Program;</li> <li>e) Approve and authorize the Director of the Purchasing that any such revisions a authorizations, including applicable waivers of a significant physical impact on the environment. PUBLIC HEALTH DEPARTMENT</li> <li>1. Board Letter</li> </ul>	<ul> <li>6/5/2018 Final action: 6/5/2018</li> <li>Consider recommendations regarding Waivers of Competition under Count the purchase of pharmaceuticals for the 340B Contract Pharmacy Network</li> <li>a) Authorize the Purchasing Manager to procure pharmaceuticals for the 3 Network Program from AmerisourceBergen Drug Company (not a local ver competitive bidding since Contract Pharmacies and Amerisource Bergen exclusivity agreements, and to ensure 340B Program compliance for an an exceed \$3,100,000.00 per year and an aggregate costs not to exceed \$9,3 July 1, 2018 through June 30, 2021;</li> <li>b) Authorize the Purchasing Manager to procure pharmaceuticals for the 3 Network Program from Cardinal Health (not a local vendor) without requirin Contract Pharmacies and Cardinal Health (not a local vendor) without requirins Program compliance for an amount up to but not to exceed \$2,500,000.00 costs not to exceed \$7,500,000.00 for the period July 1, 2018 through June 30, 2021;</li> <li>c) Authorize the Purchasing Manager to procure pharmaceuticals for the 3 Network Program from McKesson (not a local vendor) without requiring concort to exceed \$7,500,000.00 for the period July 1, 2018 through June 30, 2021;</li> <li>d) Authorize the Purchasing Manager to amend purchasing contract BL140 (increase the amount up to but not to exceed \$20,000.00 per year ar exceed \$600,000.00 for the period July 1, 2018 through June 30, 2021;</li> <li>d) Authorize the Purchasing Manager to amend purchasing contract BL140 (increase the amount strom \$150,000.00 to \$180,000.00 for Fiscal Year 2010 Contract Pharmacies and Barbara County, without returning to the Boa amendment, provided that any such revisions are within the scope of approx authorizations, including applicable waivers of competition; and</li> <li>f) Determine that these activities are exempt from California Environmental per CEQA Guideline Section 15378(b)(4), since the recommended actions activities which do no tinvolve commitment to any specific project which massignificant phys</li></ul>

Consider recommendations regarding Waivers of Competition under County Code Section 2-39 for the

## File #: 18-00411, Version: 1

purchase of pharmaceuticals for the 340B Contract Pharmacy Network Program, as follows:

a) Authorize the Purchasing Manager to procure pharmaceuticals for the 340B Contract Pharmacy Network Program from AmerisourceBergen Drug Company (not a local vendor) without requiring competitive bidding since Contract Pharmacies and Amerisource Bergen Drug Company maintain exclusivity agreements, and to ensure 340B Program compliance for an amount up to but not to exceed \$3,100,000.00 per year and an aggregate costs not to exceed \$9,300,000.00 for the period July 1, 2018 through June 30, 2021;

b) Authorize the Purchasing Manager to procure pharmaceuticals for the 340B Contract Pharmacy Network Program from Cardinal Health (not a local vendor) without requiring competitive bidding since Contract Pharmacies and Cardinal Health maintain exclusivity agreements, and to ensure 340B Program compliance for an amount up to but not to exceed \$2,500,000.00 per year and aggregate costs not to exceed \$7,500,000.00 for the period July 1, 2018 through June 30, 2021;

c) Authorize the Purchasing Manager to procure pharmaceuticals for the 340B Contract Pharmacy Network Program from McKesson (not a local vendor) without requiring competitive bidding since Contract Pharmacies and McKesson maintain exclusivity agreements, and to ensure 340B Program compliance for an amount up to but not to exceed \$200,000.00 per year and aggregate costs not to exceed \$600,000.00 for the period July 1, 2018 through June 30, 2021;

d) Authorize the Purchasing Manager to amend purchasing contract BL14003 with McKesson to increase the amount from \$150,000.00 to \$180,000.00 for Fiscal Year 2017-2018 for the 340B Contract Pharmacy Network Program;

e) Approve and authorize the Director of the Public Health Department to execute or terminate Agreements with local 340B Contract Pharmacies to ensure sustainability of the program and access for patients throughout Santa Barbara County, without returning to the Board with a separate amendment, provided that any such revisions are within the scope of approved Purchasing authorizations, including applicable waivers of competition; and

f) Determine that these activities are exempt from California Environmental Quality Act (CEQA) review per CEQA Guideline Section 15378(b)(4), since the recommended actions are government fiscal activities which do not involve commitment to any specific project which may result in a potentially significant physical impact on the environment.